APA

Babu K. G., Prabhash K., Vaid A. K., Sirohi B., Diwakar R. B., Rao R., Kar M., Malhotra H., Nag S., Goswami C., Raina V. & Mohan R. (20140626). Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study. : OncoTargets and therapy.

Chicago

Babu K Govind, Prabhash Kumar, Vaid Ashok K, Sirohi Bhawna, Diwakar Ravi B, Rao Raghunadha, Kar Madhuchanda, Malhotra Hemant, Nag Shona, Goswami Chanchal, Raina Vinod and Mohan Ravi. 20140626. Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study. : OncoTargets and therapy.

Harvard

Babu K. G., Prabhash K., Vaid A. K., Sirohi B., Diwakar R. B., Rao R., Kar M., Malhotra H., Nag S., Goswami C., Raina V. and Mohan R. (20140626). Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study. : OncoTargets and therapy.

MLA

Babu K Govind, Prabhash Kumar, Vaid Ashok K, Sirohi Bhawna, Diwakar Ravi B, Rao Raghunadha, Kar Madhuchanda, Malhotra Hemant, Nag Shona, Goswami Chanchal, Raina Vinod and Mohan Ravi. Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study. : OncoTargets and therapy. 20140626.